AU2005251839A1 - Pyridine analogs as C5a antagonists - Google Patents

Pyridine analogs as C5a antagonists Download PDF

Info

Publication number
AU2005251839A1
AU2005251839A1 AU2005251839A AU2005251839A AU2005251839A1 AU 2005251839 A1 AU2005251839 A1 AU 2005251839A1 AU 2005251839 A AU2005251839 A AU 2005251839A AU 2005251839 A AU2005251839 A AU 2005251839A AU 2005251839 A1 AU2005251839 A1 AU 2005251839A1
Authority
AU
Australia
Prior art keywords
6alkyl
isopropylphenyl
tetrahydroquinoline
carboxamide
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005251839A
Other languages
English (en)
Inventor
Nicolas Lachance
Yves Leblanc
Patrick Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of AU2005251839A1 publication Critical patent/AU2005251839A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2005251839A 2004-06-10 2005-06-07 Pyridine analogs as C5a antagonists Abandoned AU2005251839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57850004P 2004-06-10 2004-06-10
US60/578,500 2004-06-10
PCT/CA2005/000891 WO2005121095A1 (en) 2004-06-10 2005-06-07 Pyridine analogs as c5a antagonists

Publications (1)

Publication Number Publication Date
AU2005251839A1 true AU2005251839A1 (en) 2005-12-22

Family

ID=35502992

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005251839A Abandoned AU2005251839A1 (en) 2004-06-10 2005-06-07 Pyridine analogs as C5a antagonists

Country Status (7)

Country Link
US (2) US7429666B2 (enExample)
EP (1) EP1758865A4 (enExample)
JP (1) JP2008501722A (enExample)
CN (1) CN1968931A (enExample)
AU (1) AU2005251839A1 (enExample)
CA (1) CA2568673A1 (enExample)
WO (1) WO2005121095A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
WO2007100852A1 (en) * 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors
WO2008009062A1 (en) * 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
CN101541782A (zh) * 2006-10-04 2009-09-23 先灵公司 作为凝血酶受体拮抗剂的二环和三环衍生物
CN103168031A (zh) * 2010-10-20 2013-06-19 霍夫曼-拉罗奇有限公司 作为ampk活化剂的四氢喹啉衍生物
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
CN108508130B (zh) * 2018-04-11 2020-01-17 国家烟草质量监督检验中心 一种超高效合相色谱-串联质谱技术拆分、测定手性农药甲霜灵和烯酰吗啉对映体的方法
WO2022266368A1 (en) * 2021-06-16 2022-12-22 The Cleveland Clinic Foundation Protease inhibitors and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855297B2 (en) 2000-09-14 2010-12-21 Mitsubishi Tanabe Pharma Corporation Amide derivatives and medicinal use thereof
CA2479930A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists

Also Published As

Publication number Publication date
EP1758865A1 (en) 2007-03-07
CA2568673A1 (en) 2005-12-22
EP1758865A4 (en) 2010-07-21
US20090023774A1 (en) 2009-01-22
CN1968931A (zh) 2007-05-23
JP2008501722A (ja) 2008-01-24
US7429666B2 (en) 2008-09-30
WO2005121095A1 (en) 2005-12-22
US20050277644A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US20090023774A1 (en) Pyridine analogs as C5A antagonists
KR100341683B1 (ko) 무스카린작용제활성을갖는콜린성시스템에작용하는아자스피로화합물
US12221441B2 (en) Plasma kallikrein inhibitors and uses thereof
KR102317480B1 (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
DE60022523T2 (de) Aminopiperidinderivate als antibakterielles arzneimittel
US8293759B2 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US20090227571A1 (en) Androgen Receptor Modulator Compounds and Methods
KR20220092920A (ko) 헬리오스의 소분자 분해제 및 사용 방법
KR20160035068A (ko) 피롤로피리딘 또는 피라졸로피리딘 유도체
WO2011092293A2 (en) Cyclohexyl amide derivatives as crf receptor antagonists
US20080234318A1 (en) Chemical Compounds
TW202404969A (zh) 用於治療疼痛之雜芳基化合物
JP2000501432A (ja) 新規インドール―２，３―ジオン―３―オキシム誘導体
US20100137276A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
WO2015102929A1 (en) Tricyclic sulfonamide derivatives
JP2018150349A (ja) ヘテロアリール化合物及びその使用方法
JP7561285B2 (ja) 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用
KR960007864B1 (ko) 설포닐데카하이드로-8H-이소퀴노[2,1-g][1,6]-나프티리딘, 및 그의 광학 이성체 및 관련 화합물
JP2022552693A (ja) Ｐｄ－ｌ１拮抗薬化合物
US5565453A (en) Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
DK169731B1 (da) Carbolinderivater, farmaceutiske præparater som indeholder dem, fremgangsmåde til fremstilling af disse præparater samt fremgangsmåde til fremstilling af carbolinderivaterne
US8785482B2 (en) Cyclohexene benzotriazole derivatives
CA3012583A1 (en) Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
WO2024073282A2 (en) Heterocycles as modulators of nsd activity
CA3204133A1 (en) Indole derivatives as kinase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application